Tessera Defense & Homeland Security Inc. (HLSQ) shareholders
Close on Nov 9, 2026Market cap $2.94MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%) | 2,494,197 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Geneva Holding Company (GHC) SA Joint filing with Rodney Hodges (7.60%), POD Sarl (7.60%) and 3 more | 1,970,403 | 7.60% | 13G (passive) | Apr 21, 2025 |
| Morgan Stanley & Co. LLC Joint filing with Morgan Stanley (7.10%) | 1,854,032 | 7.10% | 13G (passive) | Jun 30, 2025 |
| Menachem Shalom Joint filing with Water IO Ltd. (16.57%), Star 26 Capital Inc. (16.57%) and 1 more | 1,600,000 | 20.40% | 13D (active) amendment | Apr 10, 2026 |
| Deerfield Management Company, L.P. Joint filing with James E. Flynn (8.09%) | 889,928 | 8.09% | 13D (active) amendment | May 26, 2026 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (7.13%), Daniel Mack (7.13%) | 730,551 | 7.13% | 13G (passive) amendment | Jun 30, 2026 |
| Gur Aryeh Segal Joint filing with Mandragola Ltd. (9.99%) | 553,800 | 9.99% | 13G (passive) | Apr 13, 2026 |
| Ram Naim | 477,600 | 5.30% | 13D (active) amendment | Sep 30, 2026 |
| Pyu Pyu Capital, LLC Joint filing with Reuven Yeganeh (19.99%) | 381,422 | 19.99% | 13D (active) | Dec 26, 2025 |
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (9.99%), Wilmot B. Harkey (9.99%) | 156,696 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| POD Sarl Joint filing with Rodney Hodges (5.20%), Geneva Holding Company (GHC) SA (5.20%) and 3 more | 82,618 | 5.20% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HLSQ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 127,000 | 0.48% | $430.46K | +115,520 | 0.01% |
| Commonwealth Equity Services, LLC | 2,341 | 0.01% | $8.14K | New | 0.00% |
| Ikarian Capital, LLC | 1,947 | 0.01% | $6.77K | – | 0.00% |
| Kovack Advisors, Inc. | 1,720 | 0.01% | $5.98K | New | 0.00% |
| JPMorgan Chase & Co | 154 | 0.00% | $552 | −1,260 | 0.00% |
| Barclays PLC | 132 | 0.00% | $458 | – | 0.00% |
| SBI Securities Co., Ltd. | 51 | 0.00% | $176 | +49 | 0.00% |
| Danske Bank A/S | 0 | 0.00% | $0 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 0 | 0.00% | $0 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 9 | 0M | 0.5% | 3 / 2 | 1 / 6 | 0M | 0M |
| Q1 2026 | 13 | 0M | 0.1% | 4 / 0 | 1 / 2 | 0M | 0M |
| Q4 2025 | 11 | 0M | 0.1% | 2 / 2 | 3 / 10 | 0M | 0M |
| Q3 2025 | 19 | 0M | 0.2% | 5 / 2 | 3 / 4 | 0M | 0M |
| Q2 2025 | 19 | 0M | 0.2% | 3 / 0 | 2 / 5 | 0M | 0M |
| Q1 2025 | 21 | 0M | 0.3% | 4 / 5 | 2 / 1 | 0M | 0M |
| Q4 2024 | 18 | 0M | 0.2% | 7 / 1 | 2 / 4 | 0M | 0M |
| Q3 2024 | 15 | 0M | 0.2% | 8 / 2 | 1 / 4 | 0M | 0M |
| Q2 2024 | 11 | 0M | 0.0% | 3 / 2 | 1 / 2 | 0M | 0M |
| Q1 2024 | 10 | 0M | 0.0% | 3 / 0 | 3 / 7 | 0M | 0M |
| Q4 2023 | 14 | 0M | 0.0% | 4 / 1 | 3 / 1 | 0M | 0M |
| Q3 2023 | 11 | 0M | 0.0% | 2 / 0 | 3 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan Eitan Solomon | Chief Executive Officer, Director | 126,748 | 0.47% | Apr 21, 2025 |
| Merav Bassan | Chief Development Officer | 79,597 | 0.30% | Apr 21, 2025 |
| Marina Wolfson | Chief Financial Officer | 68,545 | 0.26% | Apr 21, 2025 |
| Reuven Yeganeh | Director, 10% owner | 0 | – | Mar 18, 2026 |
| Liat Cohavi Bidas | Director | – | – | Mar 3, 2026 |
| James E. Flynn | Director | – | – | Apr 23, 2025 |
| Deerfield Healthcare Innovations Fund II, L.P. | Director | – | – | Apr 23, 2025 |
| Deerfield Mgmt V, L.P. | Director | – | – | Apr 23, 2025 |
| Deerfield Private Design Fund V, L.P. | Director | – | – | Apr 23, 2025 |
| Deerfield Mgmt HIF, L.P. | Director | 17,876,098 | 66.89% | Apr 23, 2025 |
| Deerfield Management Company, L.P. | Director | 2,494,108 | 9.33% | Apr 23, 2025 |
| Russell Greig | Director | 3,750 | 0.01% | Apr 21, 2025 |
| Jonathan S. Leff | Director | – | – | Apr 21, 2025 |
| Eddie Williams | Director | – | – | Apr 21, 2025 |
| Jesse Goodman | Director | – | – | Apr 21, 2025 |
| Susan Blum | Director | – | – | Apr 21, 2025 |
| Alan Charles Moses | Director | 5,000 | 0.02% | Apr 21, 2025 |
| Gregory Louis Merril | Director | – | – | Apr 21, 2025 |
| Fibrosis Foundation Cystic | 10% owner | 1,787,758 | 6.69% | Mar 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Reuven Yeganeh Director, 10% owner | Mar 17, 2026 | Sale | −530,000 | $5.00 | $2.65M | 0 |
| Reuven Yeganeh Director, 10% owner | Mar 17, 2026 | Conversion | +530,000 | $2.00 | $1.06M | 530,000 |
| Reuven Yeganeh Director, 10% owner | Mar 16, 2026 | Conversion | +450,000 | $2.00 | $900.00K | 450,000 |
| Reuven Yeganeh Director, 10% owner | Mar 16, 2026 | Sale | −450,000 | $5.00 | $2.25M | 0 |
| Reuven Yeganeh Director, 10% owner | Mar 13, 2026 | Conversion | +370,000 | $2.00 | $740.00K | 370,000 |
| Reuven Yeganeh Director, 10% owner | Mar 13, 2026 | Sale | −370,000 | $5.00 | $1.85M | 0 |
| Reuven Yeganeh Director, 10% owner | Mar 12, 2026 | Sale | −300,000 | $5.00 | $1.50M | 0 |
| Reuven Yeganeh Director, 10% owner | Mar 11, 2026 | Conversion | +300,000 | $2.00 | $600.00K | 30,000 |
| Marina Wolfson Chief Financial Officer | Apr 14, 2025 | Award | +68,545 | – | – | 68,545 |
| Merav Bassan Chief Development Officer | Apr 14, 2025 | Award | +79,597 | – | – | 79,597 |
| Jonathan Eitan Solomon Chief Executive Officer, Director | Apr 14, 2025 | Award | +126,748 | – | – | 126,748 |
| Jonathan Eitan Solomon Chief Executive Officer, Director | Apr 14, 2025 | Award | +126,748 | – | – | 126,748 |
| Marina Wolfson Chief Financial Officer | Apr 14, 2025 | Award | +68,545 | – | – | 68,545 |
| Merav Bassan Chief Development Officer | Apr 14, 2025 | Award | +79,597 | – | – | 79,597 |
| Deerfield Management Company, L.P. Director | Feb 27, 2025 | Option exercise | +353,249 | $0.93 | $328.52K | 1,247,054 |
| Deerfield Management Company, L.P. Director | Feb 27, 2025 | Option exercise | +353,249 | $0.93 | $328.52K | 1,247,054 |
| Jonathan Eitan Solomon Chief Executive Officer, Director | Sep 16, 2024 | Award | +50,556 | – | – | 53,056 |
| Merav Bassan Chief Development Officer | Sep 16, 2024 | Award | +31,749 | – | – | 31,749 |
| Assaf Oron Chief Business Officer | Sep 16, 2024 | Award | +25,804 | – | – | 25,804 |
| Fibrosis Foundation Cystic 10% owner | Jul 15, 2024 | Conversion | +854,700 | – | – | 1,787,758 |
| Deerfield Mgmt HIF, L.P. Director | Jul 15, 2024 | Option exercise | +5,883,000 | – | – | 8,938,049 |
| Deerfield Mgmt HIF, L.P. Director | Jul 15, 2024 | Option exercise | +5,883,000 | – | – | 8,938,049 |
| Carl L. Gordon 10% owner | May 15, 2024 | Option exercise | +9,280,408 | $0.24 | $2.23M | 13,797,997 |
| Carl L. Gordon 10% owner | May 15, 2024 | Sale | −24,344 | $0.38 | $9.25K | 13,773,653 |
| Fibrosis Foundation Cystic 10% owner | May 15, 2024 | Option exercise | +4,778,265 | – | – | 9,330,580 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Mar 15, 2024 | Award | +3,055,049 | – | – | 3,055,049 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Mar 15, 2024 | Award | +3,055,049 | – | – | 3,055,049 |
| Assaf Oron Chief Business Officer | Nov 29, 2023 | Sale | −2,056 | $0.34 | $699 | 0 |
| Assaf Oron Chief Business Officer | Nov 29, 2023 | Sale | −3,414 | $0.35 | $1.19K | 2,056 |
| Assaf Oron Chief Business Officer | Nov 29, 2023 | Sale | −5,444 | $0.40 | $2.18K | 5,470 |
| Assaf Oron Chief Business Officer | May 22, 2023 | Buy | +3,192 | $0.27 | $862 | 10,914 |
| Assaf Oron Chief Business Officer | May 19, 2023 | Buy | +6,521 | $0.28 | $1.83K | 7,722 |
| Assaf Oron Chief Business Officer | May 18, 2023 | Buy | +1,201 | $0.27 | $324 | 1,201 |
| Israel GP Ltd. OrbiMed 10% owner | Feb 27, 2023 | Buy | +348,000 | $0.25 | $87.00K | 3,161,489 |
| Chidozie Ugwumba – | Nov 4, 2022 | Sale | −1,501 | $0.38 | $570 | 2,997,025 |
| Chidozie Ugwumba – | Nov 3, 2022 | Sale | −2,000 | $0.37 | $740 | 2,998,526 |
| Chidozie Ugwumba – | Nov 2, 2022 | Sale | −2,416 | $0.36 | $870 | 3,000,526 |
| Chidozie Ugwumba – | Nov 1, 2022 | Sale | −1,300 | $0.36 | $468 | 3,002,942 |
| Chidozie Ugwumba – | Oct 31, 2022 | Sale | −3,300 | $0.37 | $1.22K | 3,004,242 |
| Chidozie Ugwumba – | Oct 28, 2022 | Sale | −1,526 | $0.36 | $549 | 3,007,542 |
| Chidozie Ugwumba – | Oct 27, 2022 | Sale | −1,505 | $0.36 | $542 | 3,009,068 |
| Chidozie Ugwumba – | Oct 26, 2022 | Sale | −12,500 | $0.35 | $4.38K | 3,010,573 |
| Chidozie Ugwumba – | Oct 25, 2022 | Sale | −3,072 | $0.37 | $1.14K | 3,023,073 |
| Chidozie Ugwumba – | Oct 24, 2022 | Sale | −5,900 | $0.35 | $2.07K | 3,026,145 |
| Chidozie Ugwumba – | Oct 21, 2022 | Sale | −5,400 | $0.37 | $2.00K | 3,032,045 |
| Chidozie Ugwumba – | Oct 20, 2022 | Sale | −6,636 | $0.37 | $2.46K | 3,037,445 |
| Chidozie Ugwumba – | Oct 19, 2022 | Sale | −4,501 | $0.37 | $1.67K | 3,044,081 |
| Chidozie Ugwumba – | Oct 18, 2022 | Sale | −15,300 | $0.35 | $5.36K | 3,048,582 |
| Chidozie Ugwumba – | Oct 17, 2022 | Sale | −8,098 | $0.34 | $2.75K | 3,063,882 |
| Chidozie Ugwumba – | Oct 14, 2022 | Sale | −3,420 | $0.33 | $1.13K | 3,071,980 |
| Chidozie Ugwumba – | Oct 13, 2022 | Sale | −11,314 | $0.33 | $3.73K | 3,075,400 |
| Chidozie Ugwumba – | Oct 12, 2022 | Sale | −9,700 | $0.33 | $3.20K | 3,086,714 |
| Chidozie Ugwumba – | Oct 11, 2022 | Sale | −5,988 | $0.33 | $1.98K | 3,096,414 |
| Chidozie Ugwumba – | Oct 10, 2022 | Sale | −10,043 | $0.33 | $3.31K | 3,102,402 |
| Chidozie Ugwumba – | Oct 7, 2022 | Sale | −24,708 | $0.36 | $8.89K | 3,112,445 |
| Chidozie Ugwumba – | Oct 6, 2022 | Sale | −25,098 | $0.44 | $11.04K | 3,137,153 |
| Chidozie Ugwumba – | Oct 5, 2022 | Sale | −46,785 | $0.44 | $20.59K | 3,162,251 |
| Chidozie Ugwumba – | Oct 4, 2022 | Sale | −19,200 | $0.34 | $6.53K | 3,209,036 |
| Chidozie Ugwumba – | Oct 3, 2022 | Sale | −15,022 | $0.33 | $4.96K | 3,228,236 |
| Chidozie Ugwumba – | Sep 30, 2022 | Sale | −8,662 | $0.36 | $3.12K | 3,243,258 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 2 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tessera Defense & Homeland Security's stock actually held short. Settlement fails (shares not delivered on time) peaked at 417,396 shares on Sep 2, 2026 over the last 90 days.
See a number that looks wrong?